Jane Street’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $53.7K | Sell |
31,971
-1,358,099
| -98% | -$1.97M | ﹤0.01% | 10904 |
|
|
2026
Q1 | $1.83M | Sell |
1,390,070
-110,448
| -7% | -$198K | ﹤0.01% | 5260 |
|
|
2025
Q4 | $2.81M | Buy |
1,500,518
+1,263,495
| +533% | +$2.43M | ﹤0.01% | 4157 |
|
|
2025
Q3 | $303K | Buy |
+237,023
| New | +$321K | ﹤0.01% | 8877 |
|
|
2025
Q2 | – | Sell |
-314,631
| Closed | -$363K | – | 10522 |
|
|
2025
Q1 | $371K | Sell |
314,631
-111,371
| -26% | -$171K | ﹤0.01% | 7440 |
|
|
2024
Q4 | $780K | Sell |
426,002
-2,245,267
| -84% | -$4.38M | ﹤0.01% | 5852 |
|
|
2024
Q3 | $4.54M | Buy |
2,671,269
+966,778
| +57% | +$1.59M | ﹤0.01% | 3016 |
|
|
2024
Q2 | $2.34M | Buy |
1,704,491
+1,183,680
| +227% | +$2.39M | ﹤0.01% | 4221 |
|
|
2024
Q1 | $1.95M | Buy |
520,811
+33,626
| +7% | +$197K | ﹤0.01% | 4166 |
|
|
2023
Q4 | $4.78M | Buy |
487,185
+236,487
| +94% | +$1.93M | ﹤0.01% | 2921 |
|
|
2023
Q3 | $2.09M | Sell |
250,698
-29,304
| -10% | -$335K | ﹤0.01% | 3984 |
|
|
2023
Q2 | $3.72M | Buy |
280,002
+203,620
| +267% | +$2.47M | ﹤0.01% | 3163 |
|
|
2023
Q1 | $885K | Sell |
76,382
-185,179
| -71% | -$1.84M | ﹤0.01% | 5234 |
|
|
2022
Q4 | $2.14M | Sell |
261,561
-18,544
| -7% | -$160K | ﹤0.01% | 3772 |
|
|
2022
Q3 | $1.63M | Buy |
280,105
+148,841
| +113% | +$854K | ﹤0.01% | 4554 |
|
|
2022
Q2 | $580K | Buy |
131,264
+53,792
| +69% | +$327K | ﹤0.01% | 6466 |
|
|
2022
Q1 | $705K | Sell |
77,472
-141,218
| -65% | -$1.63M | ﹤0.01% | 6837 |
|
|
2021
Q4 | $4.47M | Buy |
218,690
+150,518
| +221% | +$3.63M | ﹤0.01% | 3034 |
|
|
2021
Q3 | $1.74M | Buy |
68,172
+5,366
| +9% | +$159K | ﹤0.01% | 4756 |
|
|
2021
Q2 | $2.2M | Sell |
62,806
-137,226
| -69% | -$3.99M | ﹤0.01% | 4157 |
|
|
2021
Q1 | $6.66M | Sell |
200,032
-2,760
| -1% | -$96.6K | ﹤0.01% | 2014 |
|
|
2020
Q4 | $5.26M | Buy |
202,792
+150,736
| +290% | +$2.56M | ﹤0.01% | 2076 |
|
|
2020
Q3 | $514K | Buy |
52,056
+35,042
| +206% | +$202K | ﹤0.01% | 5108 |
|
|
2020
Q2 | $58K | Buy |
+17,014
| New | +$57.9K | ﹤0.01% | 6837 |
|
|
2020
Q1 | – | Sell |
-69,362
| Closed | -$357K | – | 5794 |
|
|
2019
Q4 | $357K | Buy |
69,362
+30,497
| +78% | +$155K | ﹤0.01% | 4084 |
|
|
2019
Q3 | $201K | Buy |
+38,865
| New | +$217K | ﹤0.01% | 4644 |
|
|
2018
Q3 | – | Sell |
-12,459
| Closed | -$44K | – | 5544 |
|
|
2018
Q2 | $44K | Buy |
+12,459
| New | +$34.6K | ﹤0.01% | 4823 |
|
|
2018
Q1 | – | Sell |
-15,538
| Closed | -$41K | – | 5239 |
|
|
2017
Q4 | $41K | Sell |
15,538
-142
| -0.9% | -$497 | ﹤0.01% | 4442 |
|
|
2017
Q3 | $82K | Buy |
+15,680
| New | +$67.4K | ﹤0.01% | 4291 |
|
|
2014
Q3 | – | Sell |
-16,656
| Closed | -$103K | – | 2918 |
|
|
2014
Q2 | $103K | Buy |
+16,656
| New | +$83.4K | ﹤0.01% | 2352 |
|
|
2014
Q1 | – | Sell |
-33,778
| Closed | -$177K | – | 2961 |
|
|
2013
Q4 | $177K | Sell |
33,778
-26,632
| -44% | -$122K | ﹤0.01% | 2070 |
|
|
2013
Q3 | $333K | Buy |
+60,410
| New | +$210K | ﹤0.01% | 2006 |
|
Other funds holding PACB
AIM
NAMA
Jane Street's PACB Position: Q2 2026 in Review
Jane Street reduced its Pacific Biosciences (PACB) stake by 98% in Q2 2026, selling an estimated $1.97M and leaving 31,971 shares worth $53.7K. The position accounts for ﹤0.01% of the portfolio, ranked #10904.
Jane Street first reported a position in PACB in Q3 2013 and has held it in 32 quarters since. The position peaked at $6.66M in Q1 2021. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.
- Jane Street held 31,971 shares of Pacific Biosciences worth $53.7K as of Q2 2026.
- Jane Street sold 1,358,099 Pacific Biosciences shares in Q2 2026, an estimated $1.97M.
- Pacific Biosciences made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10904 holding.
- Jane Street first reported a position in Pacific Biosciences in Q3 2013 and has held it in 32 quarters since.
- Jane Street's Pacific Biosciences position peaked at $6.66M in Q1 2021.
- 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.
Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.